UY27583A1 - Anticuerpo que inhibe la aactividad del factor de las celulas precursoras y su uso para el tratamiento del asma - Google Patents

Anticuerpo que inhibe la aactividad del factor de las celulas precursoras y su uso para el tratamiento del asma

Info

Publication number
UY27583A1
UY27583A1 UY27583A UY27583A UY27583A1 UY 27583 A1 UY27583 A1 UY 27583A1 UY 27583 A UY27583 A UY 27583A UY 27583 A UY27583 A UY 27583A UY 27583 A1 UY27583 A1 UY 27583A1
Authority
UY
Uruguay
Prior art keywords
cell factor
asthma
precursor cell
activity
treatment
Prior art date
Application number
UY27583A
Other languages
English (en)
Inventor
Toshihiko Takeuchi
Adrian Tomkinson
Steven Neben
Original Assignee
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Corp filed Critical Bayer Corp
Publication of UY27583A1 publication Critical patent/UY27583A1/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Abstract

La presente invención provee de anticuerpos humanos específicos para el factor de la células precursoras que contienen por lo menos una CDR derivadas de una biblioteca combinatoria de anticuerpos. La invención provee, además de composiciones farmacéuticas que comprenden los anticuerpos y métodos para tratar al asma. La invención provee, en forma adicional, de métodos para detectar al factor de las células huésped usando los anticuerpos.
UY27583A 2001-12-17 2002-12-13 Anticuerpo que inhibe la aactividad del factor de las celulas precursoras y su uso para el tratamiento del asma UY27583A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34217401P 2001-12-17 2001-12-17

Publications (1)

Publication Number Publication Date
UY27583A1 true UY27583A1 (es) 2003-06-30

Family

ID=23340685

Family Applications (1)

Application Number Title Priority Date Filing Date
UY27583A UY27583A1 (es) 2001-12-17 2002-12-13 Anticuerpo que inhibe la aactividad del factor de las celulas precursoras y su uso para el tratamiento del asma

Country Status (8)

Country Link
US (2) US7285640B2 (es)
AR (1) AR037756A1 (es)
AU (1) AU2002361720A1 (es)
GT (1) GT200200279A (es)
HN (1) HN2002000366A (es)
TW (1) TW200305435A (es)
UY (1) UY27583A1 (es)
WO (1) WO2003051311A2 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658924B2 (en) * 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
AR037756A1 (es) * 2001-12-17 2004-12-01 Bayer Corp Anticuerpo que inhibe la actividad del factor de las celulas precursoras y su uso para el tratamiento del asma.
WO2006002064A2 (en) * 2004-06-14 2006-01-05 Aerovance, Inc. Antibody inhibiting stem cell factor activity and use for treatment of asthma
TWI306862B (en) * 2005-01-03 2009-03-01 Hoffmann La Roche Antibodies against il-13 receptor alpha 1 and uses thereof
ES2577292T3 (es) * 2005-11-07 2016-07-14 Genentech, Inc. Polipéptidos de unión con secuencias hipervariables de VH/VL diversificadas y consenso
NZ581468A (en) * 2007-06-25 2012-09-28 Esbatech Alcon Biomed Res Unit Methods of modifying antibodies, and modified antibodies with improved functional properties
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
WO2009135001A2 (en) * 2008-04-30 2009-11-05 University Of Pittsburgh- Commonwealth System Of Higher Education Methods and compositions for regulating th2 and th17 responses
CA2737351A1 (en) * 2008-09-26 2010-04-01 Wyeth Llc Single chain antibody library design
BR112013017585A2 (pt) * 2011-01-10 2020-11-24 The Regents Of The University Of Michigan inibidor do fator de células-tronco
KR101384360B1 (ko) * 2012-05-04 2014-04-14 아주대학교산학협력단 Ｓｃｆ 또는 이의 수용체를 억제하는 물질을 포함하는 혈관 투과성 관련 질환의 치료 또는 예방용 조성물
WO2015006554A1 (en) 2013-07-10 2015-01-15 The Regents Of The University Of Michigan Therapeutic antibodies and uses thereof
MA45408A (fr) 2016-06-17 2019-04-24 Magenta Therapeutics Inc Compositions et procédés pour la déplétion des cellules cd117+
WO2019066093A1 (ko) * 2017-09-26 2019-04-04 주식회사 와이바이오로직스 Scf 특이적 항체
CN114729036A (zh) 2019-09-16 2022-07-08 奥普西迪奥有限责任公司 抗干细胞因子抗体及其使用方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2149329C (en) 1992-11-13 2008-07-15 Darrell R. Anderson Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma
US6187559B1 (en) * 1997-08-28 2001-02-13 Novartis Ag Phospholipase D gene
US6576812B1 (en) * 1999-05-06 2003-06-10 The Trustees Of Columbia University In The City Of New York Compound screening assays using a transgenic mouse model of human skin diseases
EP1285081A2 (en) * 2000-05-30 2003-02-26 ICH Productions Limited Improved methods of transfection
AR037756A1 (es) * 2001-12-17 2004-12-01 Bayer Corp Anticuerpo que inhibe la actividad del factor de las celulas precursoras y su uso para el tratamiento del asma.

Also Published As

Publication number Publication date
WO2003051311A3 (en) 2004-09-30
AR037756A1 (es) 2004-12-01
AU2002361720A1 (en) 2003-06-30
GT200200279A (es) 2003-07-18
US20050112698A1 (en) 2005-05-26
AU2002361720A8 (en) 2003-06-30
WO2003051311A2 (en) 2003-06-26
TW200305435A (en) 2003-11-01
US20030194405A1 (en) 2003-10-16
US7285640B2 (en) 2007-10-23
HN2002000366A (es) 2003-04-21

Similar Documents

Publication Publication Date Title
UY27583A1 (es) Anticuerpo que inhibe la aactividad del factor de las celulas precursoras y su uso para el tratamiento del asma
NO20170633A1 (no) Forbindelser av indolamin-2,3-dioksygenase for anvendelse i behandling av kreft i kombinasjon med et anti-PD-1 antistoff .
Virard et al. Cold atmospheric plasma induces a predominantly necrotic cell death via the microenvironment
UY28342A1 (es) Nuevos compuestos
ECSP088440A (es) Imidazopirazinas como inhibidores de proteinquinasa
EA200501586A1 (ru) Фармацевтические продукты
BRPI0509172A (pt) pelo menos uma entidade quìmica, composição farmacêutica, métodos para tratar um paciente, para inibir pelo menos uma enzima que utiliza atp, e para tratar pelo menos uma doença, uso de pelo menos uma entidade quìmica, e, método para a fabricação de um medicamento
BRPI0312649A2 (pt) compostos, composições farmacêuticas contendo os mesmos, e processos de uso para os mesmos.
AR057807A1 (es) Formulaciones de anticuerpo anti-cd3
CL2008001813A1 (es) Compuestos derivados de quinolin-3-carbonitrilo sustituidos con piperazina; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como artritis, inflamacion, cancer entre otras (div. sol. 266-04).
ATE430555T1 (de) Pharmazeutische zusammensetzungen zur behandlung von asthma
ES2377720T3 (es) Anticuerpos monoclonales agon�?sticos epha2 y métodos de uso de los mismos.
ES2421516T3 (es) Composiciones para tratar el cáncer usando el inhibidor de proteasomas PS-341
CL2007002017A1 (es) Compuestos derivados de [4,5']-bipirimidinil-6,4'-diamina; composicion farmaceutica; y uso como inhibidor de la actividad de cinasa en cancer de vejiga, cancer cervical y mieloma multiple.
EA200801301A1 (ru) ИНГИБИТОРЫ АКТИВНОСТИ Akt
ECSP088350A (es) Pirazolopirimidinas como inhibidores de protein quinasas
NO20083895L (no) Anti-IGF-1R human monoklonalantibody formulering
AR029851A1 (es) Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
ECSP055525A (es) Inhibidores de cinasas de tirosina
CL2011001215A1 (es) Compuestos derivados de pirimidina, inhibidores de tirosina quinasa; composiciones farmaceuticas que los comprenden; y su uso en el tratamiento y/o prevencion de cancer, enfermedades inflamatorias y enfermedades autoinmunes.
CL2008002852A1 (es) Compuestos derivados de 7-fluoro-5-metil-2-(fenilamino)-6,7,8,9-tetrahidro-5h-pirimido[4,5-b][1,4]diazepin-6(7h)-ona; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de canceer, inflamacion, alopecia, enfermedades autoinmune, cardiovasculares, infecciosas, nefrologicas, neurodfegenerativas, cutaneas y oseas.
NO20065936L (no) Sulfonyletylfosfordiamidater for anvendelse ved behandling av cancer.
UY28348A1 (es) Compuestos novedosos
BRPI0407234A (pt) Heterociclos substituìdos
BRPI0513944A (pt) forma substancialmente pura de um composto de quinazolina, uso de um composto de quinazolina e composição

Legal Events

Date Code Title Description
104 Application deemed to be withdrawn (no substantive examination fee paid)

Effective date: 20101115